Recordati stock: First-half revenue rose 6.60 percent for Recordati stock

Published on 10/22/2026 at 17:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

EBITDA rose 8.80 percent to EUR 540.20 million in the first half. Recordati stock costs EUR 52.95 on October 22, 2026 at 5:42 p.m. CEST, near the EUR 53.00 offer.

First-half results and dates

Recordati reported first-half 2026 revenue growth of 6.60 percent to EUR 1.40 billion on July 29, 2026.
EBITDA increased 8.80 percent to EUR 540.20 million with a 38.30 percent margin.
Recordati stock stood at EUR 52.95 at Lang & Schwarz on October 22, 2026 at 5:42 p.m. CEST.
Recordati plans to release third-quarter 2026 results on November 10, 2026.

Schwarzweiß-Reportagefoto von Laborpersonal bei Pipettenarbeit im Pharma-Labor — Recordati S.p.A. (IT0003828271) forscht in Pharma-Laboren, dokumentiert durch diese dokumentarische Schwarzweiß-Reportage-Aufnahme von Wissenschaftlern, Illustration mit AI erstellt.

Recordati (IT0003828271) reported first-half 2026 revenue of EUR 1.40 billion, up 6.60 percent year over year, according to the company's July 29, 2026 earnings-call transcript published by Yahoo Finance. At Lang & Schwarz, the stock stood at EUR 52.95 on October 22, 2026 at 5:42 p.m. CEST.

Rare diseases drive growth

The strongest operating contribution came from Recordati's Rare Diseases business. First-half revenue in the segment increased 17.10 percent to EUR 604.00 million, while Specialty and Primary Care revenue reached EUR 774.00 million, up 0.60 percent on a like-for-like basis at constant exchange rates, according to Yahoo Finance. Isturisa revenue grew 58.00 percent, while Enjaymo revenue increased 31.10 percent in the same period.

Stock stays below its yearly high

Recordati's EUR 52.95 price was 4.34 percent below its 52-week high of EUR 55.35 and 21.00 percent above its 52-week low of EUR 43.76 as of October 22, 2026. The stock's year-to-date gain stood at 9.19 percent on October 21, 2026. Its market capitalization was EUR 10.8 billion, and its price-to-earnings ratio was 22.25.

What does the margin say about execution?

EBITDA rose 8.80 percent to EUR 540.20 million in the first half, producing a 38.30 percent margin. Adjusted net income increased 6.70 percent to EUR 349.90 million, while reported net income grew 24.80 percent to EUR 269.70 million, according to Yahoo Finance. Recordati also generated EUR 299.40 million of free cash flow during the period and confirmed full-year 2026 revenue guidance of EUR 2.73 billion to EUR 2.80 billion.

The next scheduled catalyst is the third-quarter report. MarketScreener lists the earnings release for November 10, 2026 and the presentation for November 11, 2026. The company lists its first-half 2026 results in its investor reports archive dated July 29, 2026.

Recordati stock near EUR 53

The EUR 52.95 Lang & Schwarz price remained close to the EUR 53.00 takeover offer discussed in a report by Il Sole 24 ORE on October 14, 2026. For investors, the key contrast is between the offer level and the operating figures: rare-disease growth reached 17.10 percent, while the broader business delivered 6.60 percent revenue growth in the first half.

At Lang & Schwarz, Recordati stock was trading at EUR 52.95 on October 22, 2026 at 5:42 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Recordati stock.